Cargando…

Establishment and Validation of Nomogram Based on Combination of Pretreatment C-Reactive Protein/Albumin Ratio–EBV DNA Grade in Nasopharyngeal Carcinoma Patients Who Received Concurrent Chemoradiotherapy

BACKGROUND: A higher ratio of pretreatment C-reactive protein/albumin ratio (CAR) is associated with poor prognosis in nasopharyngeal carcinoma (NPC), and Epstein–Barr virus (EBV) DNA level is known to not only participate in the occurrence of nasopharyngeal carcinoma but also affect the development...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Zhang-Zan, Wen, Wen, Hua, Xin, Song, Chen-Ge, Bi, Xi-Wen, Huang, Jia-Jia, Xia, Wen, Yuan, Zhong-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320887/
https://www.ncbi.nlm.nih.gov/pubmed/34336633
http://dx.doi.org/10.3389/fonc.2021.583283
_version_ 1783730720293781504
author Huang, Zhang-Zan
Wen, Wen
Hua, Xin
Song, Chen-Ge
Bi, Xi-Wen
Huang, Jia-Jia
Xia, Wen
Yuan, Zhong-Yu
author_facet Huang, Zhang-Zan
Wen, Wen
Hua, Xin
Song, Chen-Ge
Bi, Xi-Wen
Huang, Jia-Jia
Xia, Wen
Yuan, Zhong-Yu
author_sort Huang, Zhang-Zan
collection PubMed
description BACKGROUND: A higher ratio of pretreatment C-reactive protein/albumin ratio (CAR) is associated with poor prognosis in nasopharyngeal carcinoma (NPC), and Epstein–Barr virus (EBV) DNA level is known to not only participate in the occurrence of nasopharyngeal carcinoma but also affect the development and prognosis of the disease. Herein, we proposed that a combination of both these markers could improve the predictive prognostic ability. METHODS: In all, 842 NPC patients who received concurrent chemoradiotherapy (CCRT) were entered in this study. We collected all patients’ blood samples and EBV DNA copy numbers within one week before any treatment. Receiver operating characteristic (ROC) curve was used to determine the optimal cut-off. We employed the Kaplan–Meier method for survival analyses and the univariate and multivariate analyses (Cox proportional hazards regression model) for statistical analysis. A nomogram was constructed based on multivariate analyses results of the validation set. The model was internally validated using 1000 bootstrap samples to avoid overfitting. Another validation of 10-fold cross-validation was also applied. Calibration curves and concordance index (C-index) were calculated to determine predictive and discriminatory capacity. RESULTS: In the whole cohort, we observed that higher CAR, EBV DNA level, and CAR-EBV DNA (C-E) grade were associated with shorter overall survival (OS) and distant metastasis-free survival (DMFS) (all P<0.05). In univariate and multivariate analyses, C-E grade was an independent prognostic factor (all P<0.05). In the training set, we gained the similar results with the whole set. According to multivariate analyses of the training set, we constructed a nomogram. The results of bootstrap samples and 10-fold cross-validation showed favorable predictive efficacy. And calibration curves of the model provided credibility to its predictive capability. CONCLUSION: C-E grade was confirmed as an independent prognostic predictor in patients with NPC who received CCRT. Higher level of pretreatment C-E grade could signify a higher risk of metastasis and shorter OS. The prognostic nomogram based on C-E grade was dependable in nasopharyngeal carcinoma patients.
format Online
Article
Text
id pubmed-8320887
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83208872021-07-30 Establishment and Validation of Nomogram Based on Combination of Pretreatment C-Reactive Protein/Albumin Ratio–EBV DNA Grade in Nasopharyngeal Carcinoma Patients Who Received Concurrent Chemoradiotherapy Huang, Zhang-Zan Wen, Wen Hua, Xin Song, Chen-Ge Bi, Xi-Wen Huang, Jia-Jia Xia, Wen Yuan, Zhong-Yu Front Oncol Oncology BACKGROUND: A higher ratio of pretreatment C-reactive protein/albumin ratio (CAR) is associated with poor prognosis in nasopharyngeal carcinoma (NPC), and Epstein–Barr virus (EBV) DNA level is known to not only participate in the occurrence of nasopharyngeal carcinoma but also affect the development and prognosis of the disease. Herein, we proposed that a combination of both these markers could improve the predictive prognostic ability. METHODS: In all, 842 NPC patients who received concurrent chemoradiotherapy (CCRT) were entered in this study. We collected all patients’ blood samples and EBV DNA copy numbers within one week before any treatment. Receiver operating characteristic (ROC) curve was used to determine the optimal cut-off. We employed the Kaplan–Meier method for survival analyses and the univariate and multivariate analyses (Cox proportional hazards regression model) for statistical analysis. A nomogram was constructed based on multivariate analyses results of the validation set. The model was internally validated using 1000 bootstrap samples to avoid overfitting. Another validation of 10-fold cross-validation was also applied. Calibration curves and concordance index (C-index) were calculated to determine predictive and discriminatory capacity. RESULTS: In the whole cohort, we observed that higher CAR, EBV DNA level, and CAR-EBV DNA (C-E) grade were associated with shorter overall survival (OS) and distant metastasis-free survival (DMFS) (all P<0.05). In univariate and multivariate analyses, C-E grade was an independent prognostic factor (all P<0.05). In the training set, we gained the similar results with the whole set. According to multivariate analyses of the training set, we constructed a nomogram. The results of bootstrap samples and 10-fold cross-validation showed favorable predictive efficacy. And calibration curves of the model provided credibility to its predictive capability. CONCLUSION: C-E grade was confirmed as an independent prognostic predictor in patients with NPC who received CCRT. Higher level of pretreatment C-E grade could signify a higher risk of metastasis and shorter OS. The prognostic nomogram based on C-E grade was dependable in nasopharyngeal carcinoma patients. Frontiers Media S.A. 2021-07-15 /pmc/articles/PMC8320887/ /pubmed/34336633 http://dx.doi.org/10.3389/fonc.2021.583283 Text en Copyright © 2021 Huang, Wen, Hua, Song, Bi, Huang, Xia and Yuan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Huang, Zhang-Zan
Wen, Wen
Hua, Xin
Song, Chen-Ge
Bi, Xi-Wen
Huang, Jia-Jia
Xia, Wen
Yuan, Zhong-Yu
Establishment and Validation of Nomogram Based on Combination of Pretreatment C-Reactive Protein/Albumin Ratio–EBV DNA Grade in Nasopharyngeal Carcinoma Patients Who Received Concurrent Chemoradiotherapy
title Establishment and Validation of Nomogram Based on Combination of Pretreatment C-Reactive Protein/Albumin Ratio–EBV DNA Grade in Nasopharyngeal Carcinoma Patients Who Received Concurrent Chemoradiotherapy
title_full Establishment and Validation of Nomogram Based on Combination of Pretreatment C-Reactive Protein/Albumin Ratio–EBV DNA Grade in Nasopharyngeal Carcinoma Patients Who Received Concurrent Chemoradiotherapy
title_fullStr Establishment and Validation of Nomogram Based on Combination of Pretreatment C-Reactive Protein/Albumin Ratio–EBV DNA Grade in Nasopharyngeal Carcinoma Patients Who Received Concurrent Chemoradiotherapy
title_full_unstemmed Establishment and Validation of Nomogram Based on Combination of Pretreatment C-Reactive Protein/Albumin Ratio–EBV DNA Grade in Nasopharyngeal Carcinoma Patients Who Received Concurrent Chemoradiotherapy
title_short Establishment and Validation of Nomogram Based on Combination of Pretreatment C-Reactive Protein/Albumin Ratio–EBV DNA Grade in Nasopharyngeal Carcinoma Patients Who Received Concurrent Chemoradiotherapy
title_sort establishment and validation of nomogram based on combination of pretreatment c-reactive protein/albumin ratio–ebv dna grade in nasopharyngeal carcinoma patients who received concurrent chemoradiotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320887/
https://www.ncbi.nlm.nih.gov/pubmed/34336633
http://dx.doi.org/10.3389/fonc.2021.583283
work_keys_str_mv AT huangzhangzan establishmentandvalidationofnomogrambasedoncombinationofpretreatmentcreactiveproteinalbuminratioebvdnagradeinnasopharyngealcarcinomapatientswhoreceivedconcurrentchemoradiotherapy
AT wenwen establishmentandvalidationofnomogrambasedoncombinationofpretreatmentcreactiveproteinalbuminratioebvdnagradeinnasopharyngealcarcinomapatientswhoreceivedconcurrentchemoradiotherapy
AT huaxin establishmentandvalidationofnomogrambasedoncombinationofpretreatmentcreactiveproteinalbuminratioebvdnagradeinnasopharyngealcarcinomapatientswhoreceivedconcurrentchemoradiotherapy
AT songchenge establishmentandvalidationofnomogrambasedoncombinationofpretreatmentcreactiveproteinalbuminratioebvdnagradeinnasopharyngealcarcinomapatientswhoreceivedconcurrentchemoradiotherapy
AT bixiwen establishmentandvalidationofnomogrambasedoncombinationofpretreatmentcreactiveproteinalbuminratioebvdnagradeinnasopharyngealcarcinomapatientswhoreceivedconcurrentchemoradiotherapy
AT huangjiajia establishmentandvalidationofnomogrambasedoncombinationofpretreatmentcreactiveproteinalbuminratioebvdnagradeinnasopharyngealcarcinomapatientswhoreceivedconcurrentchemoradiotherapy
AT xiawen establishmentandvalidationofnomogrambasedoncombinationofpretreatmentcreactiveproteinalbuminratioebvdnagradeinnasopharyngealcarcinomapatientswhoreceivedconcurrentchemoradiotherapy
AT yuanzhongyu establishmentandvalidationofnomogrambasedoncombinationofpretreatmentcreactiveproteinalbuminratioebvdnagradeinnasopharyngealcarcinomapatientswhoreceivedconcurrentchemoradiotherapy